Quartz selectively down-regulates CR1 on activated human granulocytes.
We have investigated the interaction between quartz and granulocytes with respect to complement receptor expression. When N-formylmethionyl-leucyl-phenylalanine (fMLP)-stimulated leukocytes were exposed to quartz at 37 degrees C, CR1 was down-regulated but CR3 was not affected. This was a direct effect on granulocytes because it occurred in a similar fashion when mixed leukocyte suspensions and isolated granulocyte populations were used as targets for quartz. The observed down-regulation by quartz was not affected by the microfilament-disrupting agent cytochalasin B and the total detectable pool of CR1 was reduced after quartz exposure. When protease inhibitors, such as aprotinin or phenylmethanesulfonyl fluoride, were present during quartz exposure, the down-regulation of CR1 was less pronounced, but this was not the case not when protease inhibitors such as EDTA-Na2 and pepstatin were present. Exposure to quartz was not accompanied by a pronounced release of beta-glucuronidase (marker for the primary granules) or vitamin B12 binding protein (marker for the secondary granules). In contrast to quartz, exposure to alumina did not affect the expression of CR1 and CR3. The spontaneous mobilization of CR1 at 37 degrees C was reduced when quartz was present but the CR3 mobilization was unaffected. Our results indicate that quartz induces a granule protease-dependent selective shedding of CR1 but not CR3 despite a low degree of degranulation.
Lundahl
J
J
Department of Clinical Immunology, Karolinska Hospital, Stockholm, Sweden.
Dahlgren
C
C
Eklund
A
A
Hed
J
J
Hernbrand
R
R
Tornling
G
G
D007611:Aprotinin / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects*; D004492:Edetic Acid / Q000494:pharmacology; D005966:Glucuronidase / Q000097:blood; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D010436:Pepstatins / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011791:Quartz / Q000494:pharmacology*; D017463:Receptors, Complement 3b / Q000187:drug effects* / Q000378:metabolism; D014155:Transcobalamins / Q000378:metabolism
D010436:Pepstatins; D011480:Protease Inhibitors; D017463:Receptors, Complement 3b; D014155:Transcobalamins; C014195:Streptomyces pepsin inhibitor; D011791:Quartz; D009240:N-Formylmethionine Leucyl-Phenylalanine; D007611:Aprotinin; D004492:Edetic Acid; D005966:Glucuronidase; C031375:pepstatin